Pharmaceutical

With FDA greenlight, BMS Breyanzi brings CAR-T cell therapy to CLL and SLL

Amidst the many BTK inhibitors, Breyanzi will be the first and only CAR-T cell therapy available for the treatment of CLL and SLL.

Mar 16, 2024 - 00:00
With FDA greenlight, BMS Breyanzi brings CAR-T cell therapy to CLL and SLL
Amidst the many BTK inhibitors, Breyanzi will be the first and only CAR-T cell therapy available for the treatment of CLL and SLL.
Read the original article

Tags:

Previous Article

BeiGene spin-out Pi Health raises $30m to uptick cancer trial enrolment

Next Article

FDA committee back Geron’s blood disorder drug

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Pfizer RSV vaccine wins CDC recommendation for seasonal use only

Pfizer RSV vaccine wins CDC recommendation for seasonal...

Sep 22, 2023

Novartis acquires Mariana in $1.75bn deal to strengthen radioligand portfolio 

Novartis acquires Mariana in $1.75bn deal to strengthen...

May 3, 2024

Why prefilled vial capacity is key to a competitive edge in pharmaceuticals manufacturing 

Why prefilled vial capacity is key to a competitive edg...

Sep 11, 2023